Promiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET inhibitors and their significant activity in diverse tumor models has rapidly translated into clinical studies and has motivated drug development efforts targeting non-BET BRDs. How...
Príomhchruthaitheoirí: | Picaud, S, Leonards, K, Lambert, J, Dovey, O, Wells, C, Fedorov, O, Monteiro, O, Fujisawa, T, Wang, C, Lingard, H, Tallant, C, Nikbin, N, Guetzoyan, L, Ingham, R, Ley, S, Brennan, P, Muller, S, Samsonova, A, Gingras, A, Schwaller, J, Vassiliou, G, Knapp, S, Filippakopoulos, P |
---|---|
Formáid: | Journal article |
Foilsithe / Cruthaithe: |
American Association for the Advancement of Science
2016
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Developing chemical probes for the BET bromodomains
de réir: Hewings, D, et al.
Foilsithe / Cruthaithe: (2012) -
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2012) -
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
de réir: Filippakopoulos, P, et al.
Foilsithe / Cruthaithe: (2012) -
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
de réir: Picaud, S, et al.
Foilsithe / Cruthaithe: (2013) -
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
de réir: Picaud, S, et al.
Foilsithe / Cruthaithe: (2013)